Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease  by Holgate, Stephen T
 Allergology International
 
 (2004) 
 
53
 
: 47–54
 
Review Article
 
Cytokine and anti-cytokine therapy for the treatment of 
asthma and allergic disease
 
Stephen T Holgate
 
Allergy and Infection Research Division, School of Medicine, University of Southampton, Southampton 
General Hospital, Southampton, UK
 
A
 
BSTRACT
 
Asthma is a chronic inflammatory disorder of the
airways superimposed upon structural changes that
include an increase in smooth muscle and airway wall
remodeling. In addition to a background of chronic
mediator release, asthma is characterized by consider-
able variations in airway function brought about by
important interactions with the environment, including
allergen, pollutant and virus exposure. At least in
mild–moderate disease, cytokines released from Th2
cells appear important in orchestrating the inflamma-
tion. The situation in more severe disease is com-
plicated by the superimposition of a Th1 on top of a
Th2 response. Until recently, the only controller treat-
ment for chronic asthma has been corticosteroids.
However, identification of specific effector molecules in
asthma has led to targeting of specific pathways by
using cytokines and cytokine inhibitors. Administration
of a monoclonal blocking antibody against IgE has
been shown to be highly efficacious in severe allergic
asthma, but enhancement of Th1 responses or
attempts to reduce eosinophils using anti-interleukin-5
monoclonal antibodies have no clinical benefit. In
more severe asthma, blockade of tumor necrosis
factor-
 
α
 
 using the decoy etanercept has revealed effi-
cacy in a small open study supporting the view that
Th1, in addition to Th2, pathways are important as
the disease adopts a more severe phenotype. Thus,
like atopic dermatitis, it is likely that asthma is not a
single disease, but a group of disorders that differ in
the relative contribution of specific pathophysiological
pathways.
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I
 
NTRODUCTION
 
In 1860, Henry Hyde Salter, a physician at Charing
Cross Hospital in London, described asthma as
‘. . . paroxysmal dyspnoea of a peculiar character with
intervals of healthy respiration between attacks’.
 
1
 
 In
addition, he first drew our attention to the characteristic
inflammation that infiltrates the airways in asthma and
the wide range of environmental factors that could
provoke attacks. It is clearly established that bronchial
asthma is a disorder of the conducting airways that
exhibit hyperresponsiveness to a wide variety of endog-
enous and exogenous stimuli, leading to variable airflow
obstruction. The recognition that airway inflammation
underlies at least a component of this hyperresponsive-
ness has received considerable support from the obser-
vation that inhaled and oral corticosteroids, which are
highly efficacious in controlling asthma, also have a
major impact on reducing the airway inflammatory
response.
 
2
 
 However, asthma differs from other chronic
inflammatory disorders, such as rheumatoid arthritis,
Crohn’s disease and psoriasis, in exhibiting a character-
istic cytokine response dominated by Th2 cytokines, the
majority of which are encoded in a small cluster on
chromosome 5q32–34.
 
3
 
 It has been suggested that this
coordinated regulation of the immune response in favor
of Th2 cytokines, which include interleukin (IL)-3, IL-4,
IL-5, IL-6, IL-9, IL-13 and granulocyte–macrophage
colony stimulating factor (GM-CSF), results from a
reduction in the inhibitory influence of Th1 cytokines,
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especially IL-18, IL-12 and interferon-
 
γ
 
, and, as a
consequence, results in Th2 polarization of the immune
response by default.
 
4
 
 This imbalance between Th1- and
Th2-type immunity in those destined to become
atopic manifests early in life, and possibly prenatally.
 
5
 
A number of explanations has been put forward to explain
this dysregulation in the immune response, but an
interaction between susceptibility genes and fetal pro-
gramming by the intrauterine environment appears to be
important.
 
6,7
 
The Th2-type cytokines are especially associated
with allergy and parasite immunity because of their
actions on some specific cells known to be involved in
the allergic inflammatory response.
 
8
 
 Of particular rele-
vance is the role of IgE, which provides the initial trigger
for many allergic responses. Maintenance of a persistent
Th2 response requires the obligatory presence of IL-4,
whereas switching of the lymphocytes from IgM to IgE
synthesis requires IL-4 or IL-13 acting in concert with the
adhesion molecule CD40 and its ligand, and is aug-
mented by IL-6. Proliferation, maturation and differentia-
tion of eosinophils requires IL-3, IL-5 and GM-CSF,
whereas basophils will differentiate in the presence of
IL-3 alone.
 
9
 
 Human mast cells are dependant upon the
mast cell growth factor stem cell factor (SCF; c-kit ligand),
which, in the presence of IL-6, IL-9 and transforming
growth factor (TGF)-
 
β
 
, results in the full differentiation of
mast cells containing the granule tetrameric enzyme tryp-
tase.
 
10,11
 
 Finally, IL-4 is required to provide the mast cell
with its full complement of cysteinyl and prostaglandin
(PG) D
 
2
 
-generating enzymes, as well as their receptors
and the high-affinity receptor for IgE. Based on this
network of interacting cytokines that orchestrate the aller-
gic and asthmatic inflammatory responses, effort is now
being directed at therapeutic applications to modify aller-
gic disease.
 
12,13
 
 Encouragement for believing that a hier-
archy of cytokines is involved in the pathogenesis of
allergy and asthma has come from the use of cytokines or
blocking antibodies or soluble receptors and gene-knock
out strategies in mice and the clear efficacy of anti-tumor
necrosis factor (TNF)-
 
α
 
 in other complex inflammatory
disorders, such as rheumatoid arthritis, inflammatory
bowel disease, psoriasis and sarcoidosis.
 
14–17
 
 One argu-
ment against this approach has been the concept of
cytokine redundancy. That is, if one cytokine is removed,
another takes its place. Based on the experience with
other chronic inflammatory disorders, it seems as if some
hierarchy exists in the way cytokines interact in complex
disease and, as a consequence, taking out cytokines high
up in the hierarchy should be clinically beneficial. The
recent promising results of the cytokine T lymphocyte-
associated (CTLA)-4 fusion protein in interrupting T cell
responses in rheumatoid arthritis by depriving CD80/86
on antigen-presenting cells from interacting with CD28
on T lymphocytes places the T cell high up the hierarchy
of cells involved in this disease.
 
18
 
 Our own work,
 
3,19
 
showing a sentinel role of CD28 on T cells and CD80/86
on antigen-presenting cells in maintaining Th2 responses
in allergic asthma creates a real opportunity for the
CTLA-4 fusion protein that interrupts this signaling as a
new therapeutic for chronic asthma.
 
U
 
SE
 
 
 
OF
 
 
 
BIOLOGICALS
 
 
 
IN
 
 
 
THE
 
 
 
TREATMENT
 
 
 
OF
 
 
 
ALLERGY
 
 
 
AND
 
 
 
ASTHMA
 
The first novel biological agent that has been introduced
for the treatment of asthma and food allergy is a
humanized monoclonal antibody targeted to the C
 
ε
 
3-
domain on the heavy chain of human IgE.
 
20
 
 The C
 
ε
 
3
epitope is involved in the binding of IgE to both the
 
α
 
-chain of the high-affinity receptor Fc
 
ε
 
R1 and the low-
affinity receptor Fc
 
ε
 
R2 (CD23).
 
21
 
 Administration of anti-
IgE directed to the C
 
ε
 
3 domain effectively depletes
circulating and tissue levels of IgE without cross-linking
IgE on the surface of mast cells or basophils.
 
22
 
 Omalizu-
mab, the humanized anti-IgE monoclonal antibody that
has now entered the clinic, effectively blocks both the
mast cell-dependant early and the inflammatory cell-
dependant late asthmatic reaction provoked by inhaled
allergen in parallel with a reduction in the influx of
eosinophils into the airway lumen.
 
23
 
 Phase 3 clinical
trials in adults and children with allergic asthma have
shown clinical efficacy of omalizumab (administered by
subcutaneous injection 2–4 weeks) beyond that achieved
with inhaled or oral corticosteroids.
 
24,25
 
 Another anti-IgE
(TNX-901) has also been shown to protect against
peanut-induced anaphylaxis.
 
26
 
 Omalizumab is also effi-
cacious in patients with allergic rhinitis and synergises
with antigen-specific immunotherapy in the prophylaxis
of severe allergic rhinitis (R Djukanovic 
 
et al
 
., unpubl.
obs., 2004). Regular treatment with omalizumab admin-
istered subcutaneously at 2–4 week intervals over 16–32
weeks results in a > 95% reduction in circulating eosi-
nophils, a 70% reduction in sputum eosinophils and an
80% reduction in airway tissue eosinophils in patients
with asthma, which is paralleled by loss of IgE and
Fc
 
ε
 
R1 receptors from mast cells, basophils and dendritic
cells in airway tissue. This strongly suggests that a
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significant component of the eosinophilia in allergic
asthma is dependant upon IgE and that the long-term
benefit of anti-IgE therapy may be mediated through loss
of the ability for effector cells to bind IgE in addition to
depletion of IgE itself.
 
E
 
FFECT
 
 
 
OF
 
 T
 
H
 
1 
 
CYTOKINES
 
 
 
ON
 
 
 
ASTHMA
 
The inhibitory effect of IFN-
 
γ
 
 on Th2 responses 
 
in vitro
 
and in animal models suggests that it may be of use in
the treatment of allergic disease. However, when admin-
istered by intravenous injection, IFN-
 
γ
 
 had no significant
effect on airway eosinophils and clinical responses in
patients with corticosteroid-dependant asthma.
 
27
 
 Mouse-
recombinant (mr) IL-12 administered intraperitoneally to
ovalbumen-sensitized and inhalation-challenged mice
resulted in a marked reduction in the influx of eosi-
nophils into the airway lumen, compatible with its
modifying effect via production of IFN-
 
γ
 
 acting to inhibit
Th2 responses.
 
28
 
 Human-recombinant (h) IL-12 adminis-
tered on four separate occasions to a group of allergic
asthmatic patients produced a progressive overall reduc-
tion in circulating numbers of eosinophils, but this
inhibitory effect lasted only 4–7 days after each injec-
tion.
 
29
 
 After four injections of incremental doses of
hrIL-12 over a period of 22 days, the circulating
eosinophil count fell to a nadir of 85% of the starting
baseline and was accompanied by a 50% reduction
in sputum eosinophils following allergen provocation.
However, when compared with placebo, hrIL-12 failed
to influence either the early or late allergen-provoked
asthmatic reactions or the accompanying increase in
bronchial hyperresponsivness. Intravenous hrIL-12 was
associated with a number of side-effects, including fever,
a general feeling of malaise and, in some subjects,
cardiac arrhythmia, which almost certainly will preclude
its use as a future therapeutic.
 
29
 
T
 
ARGETING
 
 IL-5
 
Interleukin-5 is a Th2 cytokine that is essential for the
formation and priming of eosinophils for mediator
secretion and the level of this cytokine has been shown
to increase in patients with active asthma.
 
30
 
 In patients
with asthma, IL-5 mRNA expression is increased both
in bronchial biopsies and in bronchoalveolar lavage
(BAL) cells, and increased release of IL-5 protein has
been detected in airway tissue, BAL and sputum follow-
ing allergen challenge of sensitized asthmatic patients.
 
9
 
Inhalation of IL-5 is associated with a sputum eosi-
nophilia and increased airway non-specific responsive-
ness. In mice whose gene for IL-5 had been deleted,
allergen sensitization and challenge failed to elicit eosi-
nophilia and, in some but not all experimental models,
this was accompanied by blockade of airway non-
specific hyperresponsivness (AHR).
 
30
 
 In naturally 
 
Ascaris
suum
 
-sensitized non-human primates, 6 months treat-
ment with a blocking anti-IL-5 monoclonal antibody
(TRFK-5) resulted in a marked reduction in AHR to
histamine, with an effect being apparent as early as
24 h after the first anti-IL-5 injection. Based on this
and a large number of animal studies, a humanized
monoclonal antibody against IL-5 has been generated
(SB240563; mepolizumab) that was a fully humanized
IgG1 kappa antibody expressed in Chinese hamster
ovary (CHO) cells.
 
31
 
 Mepolizumab exhibited high-affinity
binding to human IL-5 (K
 
d
 
 = 4.2 pmol/L), inhibited the
binding of IL-5 to the IL-5 receptor 
 
α
 
 chain and
profoundly suppressed human eosinophil differentiation,
the proliferative response of a human IL-5 receptor-
expressing cell-line and neutralized the proeosinophilic
activity of hrIL-5 in macaque monkeys as well as the
IL-5-dependent eosinophilia.
 
31
 
 When administered at a
dose of either 2.5 or 10 mg/kg as a single intravenous
injection to mildly asthmatic subjects, mepolizumab
produced a profound and long-lasting reduction in
circulating eosinophil numbers to almost undetectable
levels, with the high dose exhibiting efficacy on eosi-
nophils lasting up to 16 weeks after a single injection.
 
31
 
In those who had received placebo, inhaled allergen
provocation caused an increase in circulating eosi-
nophils over a period of 7 days; however, this pro-
eosinophilic effect of allergen challenge was totally
inhibited by anti-IL-5 treatment. Following allergen chal-
lenge, anti-IL-5 treatment at the 10 mg/kg dose reduced
sputum eosinophils by > 70%, which remained at this
reduced level up to day 30 post injection. Despite these
changes in circulating and airway luminal eosinophils,
the early and late asthmatic reaction to allergen provo-
cation was not affected by mepolizumab at either dose,
nor was their any change in baseline or post allergen
challenge non-specific AHR.
 
31
 
Because allergen provocation represents only part of
the asthmatic phenotype, the effect of anti-IL-5 treatment
on clinical asthma has been investigated. In one small
study
 
32
 
 involving patients with severe asthma, the anti-IL-5
humanized monoclonal antibody SCH 55700 was inves-
tigated. This anti-IL-5, like mepolizumab, was efficacious
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in a non-human primate model of allergic airway inflam-
mation. When administered to patients with severe
asthma, SCH 55700 was shown to have no significant
effect on lung function or other clinical end-points of
asthma control, despite again producing a profound
reduction in circulating eosinophil numbers. Of interest,
however, was a significant effect of anti-IL-5 on asthma
exacerbations. A second, larger clinical study has been
conducted on 362 patients, using the anti-IL-5 mono-
clonal antibody mepolizumab, which was administered
by subcutaneous injection on three occasions, 4 weeks
apart, at a dose of 250 mg (120 patients) or 750 mg
(116 patients) and compared with placebo (126 patients;
P Flood-Page 
 
et al.
 
, unpubl. obs., 2004). The asthmatic
patients in this study had a mean baseline forced expira-
tory volume in 1 s (FEV
 
1
 
) of 2.5 L (68% predicted) with
25% reversibility and remained symptomatic, despite the
use of over 700 
 
µ
 
g beclamethasone diproprionate (BDP)
and an average of four puffs per day of the short-acting
 
α
 
2
 
-adrenergic receptor agonist salbutamol. Over 85% of
patients were atopic and had elevated serum total IgE
levels. At both the high and low dose, mepolizumab
produced a profound reduction in circulating eosinophils
of > 90%, which was paralleled by a similar dose-
dependant reduction in sputum eosinophils. As observed
in the earlier studies, the effect of mepolizumab on circu-
lating sputum eosinophils was long lasting, with little
change in eosinophil numbers 12 weeks after the last
dose of mepolizumab. However, despite these marked
reductions in circulating and airway lumen eosinophils,
anti-IL-5 treatment had no effect compared with placebo
in a range of clinical asthma end-points, including symp-
toms, lung-function and 
 
α
 
2
 
-adrenergic receptor agonist
use. However, again at the high dose, there was a sug-
gestion anti-IL-5 reduced the number of severe asthma
exacerbations but, in this study (P Flood-Page 
 
et al.
 
,
unpubl. obs., 2004), which was not powered for this end-
point, this failed to reach statistical significance, possibly
due to the small number of exacerbations that occurred
during the trial period.
To seek an explanation for the lack of efficacy of IL-5
on clinical outcome measures of asthma, Flood-Page
 
et al
 
.
 
33
 
 conducted a study of mepolizamab in mild asth-
matic patients who underwent endobronchial and bone
marrow biopsies. Airway eosinophils and eosinophil
granule major basic protein (MBP) staining was deter-
mined in bronchial biopsies and in marrow aspirates.
Physiological indices, including FEV
 
1
 
, methacholine
responsiveness (measured as the PC
 
20
 
 methacholine) and
eosinophils in blood and sputum, were followed over
12 weeks. The anti-IL-5 treatment had an almost identi-
cal effect on circulating and sputum eosinophils, as was
observed in previous studies, but, at week 20 with active
treatment, only reduced the tissue eosinophil numbers by
55% and bone marrow eosinophils by 52%. There was
no significant effect on FEV
 
1
 
, bronchial hyperresponsive-
ness or other clinical asthma outcome measures. A
further extension of this biopsy study
 
36
 
 has shown that,
despite incomplete depletion of airway tissue of eosi-
nophils, the anti-IL-5 therapy had profound effects in
reducing staining of the laminar reticularis for tenascin-c,
perlican and lumican, proteoglycans known to contribute
towards airway remodeling in chronic asthma.
 
35,36
 
 One
possible explanation for the positive effect of anti-IL-5 in
reducing immunostaining for matrix molecules in the
biopsies is the capacity of IL-5 to drive epithelial and
fibroblast responses independently of eosinophils. What-
ever the explanation for these observations, it is of
concern that a substantial decrement of eosinophils in
airway tissue of asthmatics comparable to that achieved
with inhaled and oral corticosteroids had no effect dis-
cernable on outcome measures of chronic asthma,
including airway hyperresponsiveness.
 
37
 
It is clear that further clinical studies need to be
performed with highly selective agents that deplete the
airways of eosinophils before any final conclusions can
be drawn about the role of this cell in asthma. In this
regard, a recent bronchial biopsy study using humanized
anti-IgE (omalizumab) administered to mild asthmatic
patients similar to those used in the anti-IL-5 biopsy stud-
ies, resulted in an 80% reduction in both sputum and
tissue eosinophils, but without any significant improve-
ment in bronchial hyperresponsiveness. This further ques-
tions the previous widely held view that eosinophils are
fundamental to the pathogenesis of chronic bronchial
hyperresponsiveness in asthma. More recently, airway
eosinophils have been attributed to playing a greater role
in the pathogenesis of asthma exacerbations and also
cough-variant asthma (eosinophilic bronchitis).
 
38,39
 
 How-
ever, the previously accepted role of the eosinophil in
maintaining the chronic disordered airway function char-
acteristic of asthma is now being questioned. It has been
suggested that, in addition to IL-5, activation of the CCR3
receptor on eosinophils by chemokines such as eotaxins,
RANTES and monocyte/macrophage chemotactic peptide
(MCP) 3 may be required to draw eosinophils into the
lung and that antagonism of both IL-5 and CCR3 recep-
tors maybe necessary to totally deplete the airways of
 ANTI-CYTOKINE AND ASTHMA 51
 
these cells.
 
37
 
 The CCR3 antagonists are in clinical
development, as are blocking antibodies against eotaxin.
Their clinical evaluation in asthma is eagerly awaited.
 
I
 
NTERLEUKIN
 
-4
 
Interleukin-4 and its homolog IL-13, which shares some
but not all of its effects, are major therapeutic targets
in asthma on account of their actions on T cells, B cells
and on structural elements in the airway, including
epithelial cells promoting the production of goblet cells
and fibroblasts in augmenting airway remodeling.
 
40
 
Interleukin-4 also stabilizes the expression of vascular
cell adhesion molecule (VCAM)-1, which is involved in
the recruitment of eosinophils. The soluble IL-4 receptor
 
α
 
 (sIL-4R
 
α
 
) acts as a natural IL-4 antagonist.
 
41
 
 In two
small studies, inhalation of a single dose of recombinant
human sIL-4R (altrakincept) has been shown to be
significantly more effective than placebo at inhibiting
the decline of baseline lung function and reducing the
deterioration in asthma symptoms in patients with
moderate–severe disease when this treatment was
administered over a period of 2 weeks.
 
42,43
 
 Twelve,
once-weekly inhalations of sIL-4R was safe and more
effective than placebo in preventing deterioration of
asthma when glucocorticosteroids were discontinued.
However, in two, so far unpublished, large phase III
clinical trials in moderate asthma, altrakincept failed to
show efficacy and, as a consequence, altrakanicept has
not been further developed. Part of the difficulty with this
recombinant human protein was its rapid proteolytic
degradation in the airways and a lack of understanding
of the dose needed to optimally neutralize IL-4 in the
airways.
A mouse soluble IL-4 mutant has been shown to be an
antagonist for both IL-4 and IL-13 
 
in vitro
 
 via the forma-
tion of an unproductive complex with IL-4R
 
α
 
.
 
44 Treatment
of mice with this antagonist completely inhibited the
humoral immune response to allergen and the subse-
quent development of disordered lung function on aller-
gen challenge.44 Similarly, BAY 16–9996 administered
subcutaneously, as a human IL-4 double mutein, was
effective in reducing airway inflammation and bronchial
hyperresponsiveness in a primate model of asthma.45
This human recombinant protein was safe and well toler-
ated in mild to moderate asthmatic subjects and further
clinical trials are in progress. Human and humanized
blocking IL-4 monoclonal antibodies are also currently in
clinical development.
Interleukin-13 has recently assumed considerable
prominence as a major cytokine involved in airway
inflammation and remodeling in asthma. The IL-13α2
receptor has a much higher affinity for IL-13 than its α1
counterpart, which is responsible for the intracellular sig-
naling effects of IL-13.46 When administered to mice prior
to sensitization, soluble IL-13α2 has a profound effect in
modifying the airway inflammatory and remodeling
responses with repeated aerosol antigen challenge.47
Interleukin-13 remains a highly relevant new target for
the treatment of chronic severe asthma, using recom-
binant human IL-13α2 receptor as a molecule decoy or
blocking monoclonal antibodies.41 Both approached are
in clinical trial.
ANTI-TUMOR NECROSIS FACTOR-α
Tumor necrosis factor-α is a new therapeutic target in
chronic asthma. The expression of TNF-α is increased
in asthmatic airways in proportion to disease severity
and inhalation of recombinant TNF-α enhances bron-
chial hyperresponsivness and sputum neutrophilia in
normal subjects.48,49 In patients who have died from
asthma, TNF-α expression is increased at both the
protein and mRNA levels in a wide number of inflamma-
tory cells, including mast cells, eosinophils, T cells and
macrophages. Tumor necrosis factor-α receptors are
found on airway monocytes, macrophages, lymphocytes
and granulocytes, as well as on mast cells. We have
recently shown that TNF-α is able to enhance the
release of inflammatory mediators from human lung
mast cells through an autocrine mechanism involving
the activation of the transcription factor nuclear factor-
κB.50 Genetic studies have also revealed that the –308
promoter polymorphism of TNF-α is associated with
asthma and its severity,51 although it is not clear whether
this single nucleotide polymorphism is in linkage
disequilibrium with the adjacent gene TNF-α.52
It has also been shown that the bronchoconstrictor
response to some bronchoconstrictor stimuli (e.g. SO2 or
O3) is enhanced in subjects positive for the TNF-α –308
allele.53 A recent description of anti-TNF-α therapy using
infliximab for rheumatoid arthritis in patients with con-
comitant severe asthma or chronic obstructive pulmonary
disease revealed a marked improvement in the lung dis-
orders in parallel with improvement in the rheumatoid
arthritis.54 On this basis, we have undertaken a small
open study involving 15 patients with severe asthma
requiring a mean dose of inhaled corticosteroid
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equivalent to 2500 µg/day BDP, a mean daily oral dose
of prednisolone 12.1 mg/day, long-acting inhaled
α2-adrenergic receptor agonists and regular nebulized
salbutamol.55 After a baseline period, patients were
entered into a therapeutic trial of etanercept, a fusion
protein consisting of the extracellular ligand-binding
portion of the high-affinity human 75 kDa TNF-α recep-
tor linked to the fc-portion of human IgG1. Etanercept
serves as a decoy to inhibit both the binding of free
TNF-α and TNF-α to cell-associated TNF receptors,
thereby rendering extracellular TNF biologically inactive.
Subjects received 25 mg etanercept subcutaneously
twice a week for a period of 12 weeks and conventional
outcome measures of asthma were followed. At the end
of the 12 week period, there was a significant increase in
both FEV1 and forced vital capacity in all but one subject
and this was paralleled by a sevenfold reduction in the
area under the methacholine dose–response curve and a
halving of the mean symptom score based on the asthma
control questionnaire developed by Juniper et al.56 These
impressive results have stimulated a placebo-control trial
to investigate anti-TNF therapy in chronic severe asthma,
which is now ongoing. What this small study has shown is
that, at the severe end of the disease spectrum, blockade
of a ‘Th1’ cytokine in asthma is highly efficacious and
suggests that viewing this disease simply as a Th2 inflam-
matory response is inadequate, especially as the disease
becomes chronic and severe.57,58 What is now needed
are new studies to investigate the pathophysiology of
severe asthma compared with mild or controlled disease.
Interventions that are targeted specifically to severe
chronic asthma may also include a range of pleomorphic
cytokines, such as IL-1 and IL-6, which are known to
also be involved in inflammatory joint, bowel and skin
disease.
CONCLUDING COMMENTS
Based on the observations so far made with biological
agents, which target single molecules in asthma, it is
highly likely that asthma is not a single entity, but a series
of separate subphenotypes in which individual effector
molecules play a dominant role. Examples of this in
asthma already exist in sharing the greater efficacy of
antileukotrine therapy in patients with aspirin-intolerant
asthma, the use of antihuman allergy IgE to treat severe
allergic asthma and, based on the small study described
above, the potential impact that anti-TNF therapy may
have in patients with chronic corticosteroid refractory
disease. A key target for the future would be the
identification of biomarkers that reflect these disease
subtypes so that anti-asthma therapy can be tailored to
the individual patient’s need.
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